Modulating the Orexin Pathway: A Melatonin-Free, Peptide-Based Strategy for Restorative Sleep

Sleep disturbance remains a significant clinical challenge, with an estimated 30–40% of adults reporting difficulty falling asleep, maintaining sleep, or waking unrefreshed.¹ Insufficient or poor-quality sleep is associated with metabolic dysfunction, mood dysregulation, impaired cognitive performance, cardiovascular strain, and reduced daytime resilience. Given the individualized nature of sleep patterns and the limitations of sedative or hormone-based interventions, clinicians are increasingly seeking physiologic strategies that work with—rather than override—the body's regulatory systems.

An emerging target is the orexin (hypocretin) pathway, a central regulator of wakefulness, arousal, and circadian cortisol rhythms. Orexin signaling promotes alertness by stimulating adrenal cortisol release through the HPA axis. Under healthy physiology, orexin activity declines at night, allowing cortisol to fall and sleep onset to occur. However, stress, circadian disruption, and aging can sustain orexin activity into the evening, contributing to elevated nighttime cortisol and subsequent difficulty initiating and sustaining sleep.^2,3

Advances in peptidomics have identified plant-derived bioactive peptides that modulate peripheral orexin-related signaling. These peptides—featured in SleepTides™—were discovered using AI-driven peptide mapping and molecular docking techniques and have been shown in preclinical models to remain viable after digestion while influencing adrenal cortisol release through peripheral orexin receptors.^4,5 Importantly, these peptides provide a melatonin-free, non-sedating option for patients who are sensitive to melatonin or prefer a physiological approach to sleep regulation.

A randomized, placebo-controlled clinical trial evaluated nightly supplementation of 250 mg of these plant peptides in adults with mild to moderate sleep impairment. Participants experienced meaningful improvements in validated subjective measures, including a 3% increase in ease of getting to sleep (GTS) and an 12% increase in perceived quality of sleep (QOS) on the Leeds Sleep Evaluation Questionnaire (LSEQ).⁴ Upward trends in ease of awakening and behavior upon waking suggest support for next-day alertness and reduced morning grogginess.

Mood outcomes also improved. On the Profile of Mood States (POMS), participants receiving the peptides demonstrated improved total mood, whereas the placebo group

worsened slightly. Significant improvement in the anger subscale further highlights the relationship between sleep continuity and emotional regulation.⁴

Objective biometric data collected via Oura Ring supported these findings. Supplementation was associated with a 13-minute increase in deep sleep, a 12-minute increase in REM sleep, an average 38-minute increase in total sleep time, and a 32% increase in heart rate variability (HRV)—a key marker of autonomic recovery.⁴

With clinical benefits observed at 250 mg nightly taken 30-60 minutes prior to bedtime, SleepTides™ offers practitioners a physiologic, melatonin-free option for supporting patients experiencing stress-related or cortisol-mediated sleep disturbances.

1. Nuritas Research Group. Randomized, Single-Blind, Placebo-Controlled Study Evaluating Plant-Derived Peptides for Sleep Quality and Mood. 2024.
2. Mohan N., et al. Circadian Regulation of Cortisol and Its Impact on Sleep Architecture. 2023.
3. Franklyn-Miller A., et al. Stress-Induced Elevations of Evening Cortisol and Their Effects on Sleep Quality. 2023.
4. Nuritas Research Group. Pilot Clinical Evaluation of Plant Peptides: LSEQ, POMS, and Oura Ring Outcomes. 2024.
5. Nuritas Scientific Team. In Vitro Assessment of Plant Peptides on Orexin Receptors and Cortisol Signaling. 2023.
6. Peptidomics & AI Discovery Team. Identification and Characterization of Plant-Based Bioactive Peptides for Sleep Support. 2023.